Varian Medical Systems — Q1 FY2020 Earnings Presentation
35 slides from Varian Medical Systems's earnings presentation, Jan 29, 2020
Slide 1: First Quarter Fiscal Year 2020
First Quarter Fiscal Year 2020 January 29, 2020 Investor Relations
Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Except for historical information, this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. S
Slide 3: Agenda
Agenda Q1 FY 2020 earnings 1. First Quarter Results 2. Total Company Performance 3. Segment Performance 4. FY 2020 Guidance 5. Appendix VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY
Slide 4: Q1 FY 2020 key financial metrics
Q1 FY 2020 key financial metrics $M Q1 Y/Y Oncology Orders1 $774 8% • Core business driven by a continuous innovation cycle, while acquisitions delivering Revenues $829 12% on growth expectations Oncology $782 11% Proton Solutions $28 (28%) Other $19 n/a • Q1 Non-GAAP operating earnings grew 13% GAA
Slide 5: Long-term growth and value creation strategy
Long-term growth and value creation strategy Focusing on these Strategic enablers will deliver core business growth, global expansion and new opportunities Innovate in radiation therapy Leverage artificial intelligence, machine learning and Global Leader cloud solutions Global Leader in in Radiation
Slide 6: Executing on long-term growth strategy
Executing on long-term growth strategy Innovate Leverage Grow Artificial Intelligence, Machine Learning, Emerging Geographies, Businesses and in Radiation Therapy and Cloud Solutions Technologies KEY METRICS KEY METRICS KEY METRICS • Global market leader • Software revenues grew +13% • Interventiona
Slide 7: Varian linac net installed base
Varian linac net installed base Installed base growth Varian strengthened its global leadership in radiation therapy 8,561 • Net installed base grew +4% or 363 units, driving future recurring software and services revenues +363 • All three geographies grew respective installed (+4%) base in the quar
Slide 8: Key wins
Key wins Americas EMEA APAC Massachusetts General Hospital Brazil India – Tata Trusts Russia – Skolkovo 7 radiotherapy systems 8 Halcyon 2 TrueBeam 2 TrueBeam and 2 VitalBeam China Japan – 5 Halcyon Sagamihara Kyodo 1 Halcyon OSF Saint Francis Medical Center Israel 2 TrueBeam 1 Ethos Singapore – Aus
Slide 9: Total Company Performance
Total Company Performance varian
Slide 10: Total company results (GAAP)
Total company results (GAAP) Key P&L financial metrics VARIAN • Revenues grew double digits in the quarter driven $M Q1 FY20 Y/Y TTM Y/Y by strength across our portfolio; organic revenues Gross Orders $819 13% $3,666 14% grew 8% Revenues $829 12% $3,313 11% • R&D spend in the quarter driven by inves
Slide 11: Total company results (non-GAAP)
Total company results (non-GAAP) Key P&L financial metrics VARIAN • Revenues grew double digits in the quarter driven $M Q1 FY20 Y/Y TTM Y/Y by strength across our portfolio; organic revenues Gross Orders $819 13% $3,666 14% grew 8% Revenues $829 12% $3,313 11% • Gross Margin rate up in the quarter
Slide 12: Key balance sheet and cash flow metrics
Total company results Key balance sheet and cash flow metrics Cash & Cash Equivalents ($M) Total Debt ($M) +17% Y/Y +$544M Y/Y $800 $600 • Cash & Cash Equivalents of $722 million; majority $500 outside the U.S. $700 $400 $600 $300 • Total Debt of $544 million, up $132 million quarter- $200 over-quar
Slide 13: Capital allocation priorities
Capital allocation priorities Q1 update Long-term value creation strategy that includes balancing growth, profitability and liquidity Organic R&D and Capital • Innovations in FLASH technology, software capability, and infrastructure Investments Inorganic • Investing to build out sales and distributi
Slide 14: Segment Performance
Segment Performance varian
Slide 15: Oncology Systems segment (GAAP)
Oncology Systems segment (GAAP) Key financial metrics VARIAN • Gross Orders in the quarter and over the trailing $M Q1 FY20 Y/Y TTM Y/Y twelve months, up 8% in dollars and up 9% in Gross Orders $774 8% $3,455 8% constant currency Revenues $782 11% $3,142 11% • Revenues grew double digits driven by s
Slide 16: Oncology Systems gross orders by geography
Oncology Systems gross orders by geography APAC AMERICAS +9% Q1 Y/Y +7% Q1 Y/Y1 (+9% cc) (+7% cc) +6% TTM Y/Y +6% TTM Y/Y1 (+7% cc) (+6% cc) (1) In North America, Q1 orders growth of +4% and TTM orders growth of +6% EMEA +8% Q1 Y/Y (+11% cc) +11% TTM Y/Y 16 (+14% cc)
Slide 17: Proton Solutions segment (GAAP)
Proton Solutions segment (GAAP) Key financial metrics • Gross Orders growth driven by 1 order in the quarter VARIAN $M Q1 FY20 Y/Y TTM Y/Y • Product Revenues decline driven by project mix Gross Orders $26 399% $173 935% • Services Revenues driven by incremental rooms Revenues $28 (28%) $133 (16%) co
Slide 18: ProBeam proton therapy system sites
ProBeam proton therapy system sites 26 78 ProBeam Total Sites Rooms 11 38 Operational Operational Operational Centers Centers Under Development Sites Rooms1 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 18
Slide 19: Other segment (GAAP)
Other segment (GAAP) Key financial metrics VARIAN • Revenues from Interventional Oncology business $M Q1 FY20 Y/Y TTM Y/Y represent sales for cryoablation, embolic Gross Orders $19 n/a $38 n/a microspheres, and microwave ablation portfolio Revenues $19 n/a $38 n/a − Solid performance in China Produc
Slide 20: FY 2020 Guidance
FY 2020 Guidance varian
Slide 21: Guidance for fiscal year 2020
Varian consolidated Guidance for fiscal year 2020 VARIAN • Guidance considers projected market growth and FY18 FY19 FY20 $M Actual Actual Guidance continued momentum of Varian’s portfolio Revenues $2,919 $3,225 $3.515 to $3,612 • Guidance Assumptions Y/Y % 11% 10% 9% to 12% − Non-GAAP effective tax
Slide 22: In summary, we are…
In summary, we are… Global leader in radiation therapy Growing our net installed base driving future recurring …Driving software and services revenues toward our vision Expanding into high growth, high margin businesses of a world without fear of cancer Winning in emerging markets with our strong va
Slide 23: Appendix
Appendix
Slide 24: Non-GAAP disclosure
Non-GAAP disclosure Discussion of Non-GAAP Financial Measures This presentation includes the following non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings: organic revenue growth, non-GAAP operating earnings, non-GAAP net earnings and non-GAAP net earnings per
Slide 25: GAAP to non-GAAP reconciliation
GAAP to non-GAAP reconciliation THE FOLLOWING TABLE RECONCILES GAAP AND NON-GAAP FINANCIAL MEASURES Dollars and shares in millions, except per share amounts 1Q FY19 2Q FY19 3Q FY19 4Q FY19 1Q FY20 Non-GAAP adjustments Amortization of intangible assets and inventory step-up (1) $4.2 $6.1 $6.8 $20.0 $
Slide 26: Organic revenue growth reconciliation
Organic revenue growth reconciliation Impact Impact from $M 1Q FY19 1Q FY20 Percent Change Organic Growth from Acquisitions Foreign Exchange Total Revenues $741.0 $828.9 12 % (5) % 1 % 8 % 26
Slide 27: Total revenues by sales classification
Total revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 1Q FY20 Product revenues $400.2 $430.5 $461.3 $492.1 $421.0 Y/Y 9 % 9 % 26 % 10 % 5 % Service revenues $340.8 $348.9 $364.5 $386.8 $407.9 Y/Y 9 % 4 % 6 % 9 % 20 % Total revenues $741.0 $779.4 $825.8 $878.9 $828.9 Y/Y 9 % 7 % 1
Slide 28: Total revenues by product type
Total revenues by product type $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 1Q FY20 1Q Y/Y Hardware $347.2 $367.0 $387.9 $430.2 $359.0 3 % Oncology Systems $313.6 $339.1 $361.7 $379.2 $320.0 2 % Proton Solutions $33.6 $27.9 $24.2 $33.6 $20.1 (40)% Other — — $2.0 $17.4 $18.9 n/a Software1 $131.2 $144.2 $155.7
Slide 29: Total revenues by region
Total revenues by region $M 1Q FY19 2Q FY19 3Q FY19 4QFY19 1Q FY20 Americas revenues $350.4 $371.3 $401.2 $404.5 $402.2 Y/Y (2)% 9 % 17 % 2 % 15 % Y/Y – CC (2)% 10 % 17 % 2 % 15 % EMEA revenues $251.0 $261.5 $271.3 $289.6 $272.9 Y/Y 30 % 3 % 18 % 9 % 9 % Y/Y – CC 33 % 10 % 24 % 12 % 11 % APAC revenu
Slide 30: Total Oncology Systems revenues by sales classification
Total Oncology Systems revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 1Q FY20 Product revenues $366.6 $402.6 $433.8 $439.4 $382.0 Y/Y 8 % 11 % 33 % 9 % 4 % Y/Y – CC 9 % 14 % 36 % 10 % 5 % Service revenues $335.9 $344.2 $359.1 $380.2 $400.4 Y/Y 8 % 3 % 6 % 8 % 19 % Y/Y – CC 9 % 6
Slide 31: Total Oncology Systems revenues by region
Total Oncology Systems revenues by region $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 1Q FY20 Americas revenues $330.8 $357.1 $385.6 $377.8 $378.9 Y/Y (2)% 11 % 19 % 2 % 15 % Y/Y – CC (2)% 12 % 20 % 2 % 15 % EMEA revenues $234.5 $245.3 $256.4 $264.7 $259.8 Y/Y 28 % 2 % 23 % 6 % 11 % Y/Y – CC 31 % 9 % 30 % 9
Slide 32: Total Proton Solutions revenues by sales classification
Total Proton Solutions revenues by sales classification $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 1Q FY20 Product revenues $33.6 $27.9 $25.5 $35.3 $20.1 Y/Y 23% (7)% (33)% (19)% (40)% Service revenues $4.9 $4.7 $5.4 $6.6 $7.5 Y/Y 172% 151% 44 % 157 % 54 % Total revenues $38.5 $32.6 $30.9 $41.9 $27.6 Y/Y 32
Slide 33: Oncology Systems gross orders by region
Oncology Systems gross orders by region $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 1Q FY20 Americas orders $335.9 $366.1 $357.4 $559.0 $359.5 Y/Y 12 % 7 % (1)% 11 % 7 % Y/Y – CC 12 % 8 % (1)% 11 % 7 % EMEA orders $218.3 $233.3 $281.1 $395.9 $236.7 Y/Y 15 % 17 % 8 % 10 % 8 % Y/Y – CC 17 % 25 % 13 % 12 % 11 %
Slide 34: Condensed consolidated statements of cash flows
Condensed consolidated statements of cash flows $M 1Q FY19 2Q FY19 3Q FY19 4Q FY19 1Q FY20 Net cash provided by (used in) Operating Activities $140.9 $(13.4) $126.5 $117.8 $112.6 Net earnings 103.9 88.4 29.5 70.4 88.9 Share-based compensation expense 10.5 12.5 12.2 12.7 14.9 Depreciation 12.8 13.0 1
Slide 35: Our promise
Our promise People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer. W
Varian Medical Systems — Q1 FY2020 Earnings Presentation on 6ix